[go: up one dir, main page]

WO2004086047A3 - Diagnostics and therapeutics for diseases associated with g-protein-coupled receptor adenosine a1 (adora1) - Google Patents

Diagnostics and therapeutics for diseases associated with g-protein-coupled receptor adenosine a1 (adora1) Download PDF

Info

Publication number
WO2004086047A3
WO2004086047A3 PCT/EP2004/002734 EP2004002734W WO2004086047A3 WO 2004086047 A3 WO2004086047 A3 WO 2004086047A3 EP 2004002734 W EP2004002734 W EP 2004002734W WO 2004086047 A3 WO2004086047 A3 WO 2004086047A3
Authority
WO
WIPO (PCT)
Prior art keywords
disorders
adora1
therapeutics
diagnostics
protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2004/002734
Other languages
French (fr)
Other versions
WO2004086047A2 (en
Inventor
Stefan Golz
Ulf Brueggemeier
Andreas Geerts
Ralf Thiele
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer AG
Original Assignee
Bayer Healthcare AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Healthcare AG filed Critical Bayer Healthcare AG
Publication of WO2004086047A2 publication Critical patent/WO2004086047A2/en
Publication of WO2004086047A3 publication Critical patent/WO2004086047A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/72—Assays involving receptors, cell surface antigens or cell surface determinants for hormones
    • G01N2333/726—G protein coupled receptor, e.g. TSHR-thyrotropin-receptor, LH/hCG receptor, FSH
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • Endocrinology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

The invention provides a human ADORA1 which is associated with the cardiovascular disorders, endocrine system and hormone disorders, metabolic diseases, hematological disorders, respiratory diseases, neurological disorders and urological disorders. The invention also provides assays for the identification of compounds useful in the treatment or prevention of cardiovascular disorders, endocrine system and hormone disorders, metabolic diseases, hematological disorders, respiratory diseases, neurological disorders and urological disorders. The invention also features compounds which bind to and/or activate or inhibit the activity of ADORA1 as well as pharmaceutical compositions comprising such compounds.
PCT/EP2004/002734 2003-03-28 2004-03-17 Diagnostics and therapeutics for diseases associated with g-protein-coupled receptor adenosine a1 (adora1) Ceased WO2004086047A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP03006847.2 2003-03-28
EP03006847 2003-03-28

Publications (2)

Publication Number Publication Date
WO2004086047A2 WO2004086047A2 (en) 2004-10-07
WO2004086047A3 true WO2004086047A3 (en) 2005-01-20

Family

ID=33040915

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2004/002734 Ceased WO2004086047A2 (en) 2003-03-28 2004-03-17 Diagnostics and therapeutics for diseases associated with g-protein-coupled receptor adenosine a1 (adora1)

Country Status (1)

Country Link
WO (1) WO2004086047A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023150541A1 (en) * 2022-02-01 2023-08-10 The Uab Research Foundation Anticonvulsant and neuroprotective agent
WO2024215814A2 (en) * 2023-04-10 2024-10-17 Anand Rene Methods and pharmaceutical compositions for treating aging

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994019349A1 (en) * 1993-02-26 1994-09-01 Merrell Dow Pharmaceuticals Inc. Xanthine derivatives as adenosine a1 receptor antagonists
US5817760A (en) * 1992-03-13 1998-10-06 Merck & Co., Inc. Human A3 adenosine receptors
US6492377B1 (en) * 1998-06-25 2002-12-10 Boehringer Ingelheim Pharma Kg Imidazotriazolopyrimidines with adenosine-antagonistic activity
US20030143732A1 (en) * 2001-04-05 2003-07-31 Kathy Fosnaugh RNA interference mediated inhibition of adenosine A1 receptor (ADORA1) gene expression using short interfering RNA

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5817760A (en) * 1992-03-13 1998-10-06 Merck & Co., Inc. Human A3 adenosine receptors
WO1994019349A1 (en) * 1993-02-26 1994-09-01 Merrell Dow Pharmaceuticals Inc. Xanthine derivatives as adenosine a1 receptor antagonists
US5840729A (en) * 1993-02-26 1998-11-24 Merrell Pharmaceuticals Inc. Xanthine derivatives as adenosine A1 receptor antagonists
US6492377B1 (en) * 1998-06-25 2002-12-10 Boehringer Ingelheim Pharma Kg Imidazotriazolopyrimidines with adenosine-antagonistic activity
US20030143732A1 (en) * 2001-04-05 2003-07-31 Kathy Fosnaugh RNA interference mediated inhibition of adenosine A1 receptor (ADORA1) gene expression using short interfering RNA

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
MULLER C E: "A1-adenosine receptor antagonists", EXPERT OPINION ON THERAPEUTIC PATENTS 1997 UNITED KINGDOM, vol. 7, no. 5, 1997, pages 419 - 440, XP002295811, ISSN: 1354-3776 *

Also Published As

Publication number Publication date
WO2004086047A2 (en) 2004-10-07

Similar Documents

Publication Publication Date Title
WO2005093092A3 (en) Diagnostics and therapeutics for diseases associated with g-protein coupled receptor 44 (gpr44)
WO2004097421A3 (en) Diagnostics and therapeutics for diseases associated with calcitonin receptor-like receptor (calcrl)
WO2004099782A3 (en) Diagnostics and therapeutics for diseases associated with g-protein-coupled receptor gpr39 (gpr39)
WO2004086047A3 (en) Diagnostics and therapeutics for diseases associated with g-protein-coupled receptor adenosine a1 (adora1)
WO2005106491A3 (en) Diagnostics and therapeutics for diseases associated with serum/glucocorticoid regulated kinase 1 (sgk1)
WO2004099783A3 (en) Diagnostics and therapeutics for diseases associated with g-protein-coupled receptor ltb4 (ltb4)
WO2004086034A3 (en) Diagnostics and therapeutics for diseases associated with g-protein-coupled receptor adenosine a3(adora3)
WO2004082570A3 (en) Diagnostics and therapeutics for diseases associated with dopamine receptor d2 (drd2)
WO2004081563A3 (en) Diagnostics and therapeutics for diseases associated with phosphodiesterase 1a (pde1a)
WO2004071378A3 (en) Diagnostics and therapeutics for diseases associated with g-protein coupled receptor hm74a (hm74a)
WO2005093091A3 (en) Diagnostics and therapeutics for diseases associated with g-protein coupled receptor 26 (gpr26)
WO2004086052A3 (en) Diagnostics and therapeutics for diseases associated with g-protein-coupled receptor adenosine a2b (adora2b)
WO2005076007A3 (en) Diagnostics and therapeutics for diseases associated with g protein-coupled receptor p2y12 (p2y12)
WO2004099248A3 (en) Diagnostics and therapeutics for diseases associated with g-protein-coupled receptor agtr2 (agtr2)
WO2004099781A3 (en) Diagnostics and therapeutics for diseases associated with g-protein-coupled receptor rdc1 (rdc1)
WO2004106935A3 (en) Diagnostics and therapeutics for diseases associated with g protein-coupled receptor 103 (gpr103)
WO2005074969A3 (en) Diagnostics and therapeutics for diseases associated with human nuclear receptor nr4a1 (nr4a1)
WO2004080372A3 (en) Diagnostics and therapeutics for diseases associated with g-protein coupled proteinase activated receptor 4 (par4)
WO2004099772A3 (en) Diagnostics and therapeutics for diseases associated with g-protein-coupled receptor agtr1a (agtr1a)
WO2005100997A3 (en) Diagnostics and therapeutics for diseases associated with tachykinin receptor 3 (tacr3)
WO2005113788A3 (en) Diagnostics and therapeutics for diseases associated with g protein-coupled receptor kinase 6 (grk6)
WO2005114209A3 (en) Diagnostics and therapeutics for diseases associated with g protein-dependent receptor kinase 2 (grk2)
WO2005114210A8 (en) Diagnostics and therapeutics for diseases associated with g protein-dependent receptor kinase 3 (grk3)
WO2004097422A3 (en) Diagnostics and therapeutics for diseases associated with calcitonin receptor (calcr)
WO2005040791A3 (en) Diagnostics and therapeutics for diseases associated with somatostatin- and angiogenin-like peptide receptor (salpr)

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase